BioNote

BioNote Debt-to-Equity

Debt-to-Equity Ratio of BioNote (377740.KS) as of Oct 18, 2026.

Debt-to-Equity

0.00

YoY

-88.52%

Last updated:

Debt-to-Equity Ratio of BioNote is 2025 0.00 . Debt-to-Equity Ratio of BioNote was 2024 0.03 . It decreases by -88.52% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNote Stock analysis

What does BioNote do? BioNote Inc., headquartered in Hwaseong, South Korea, operates in the Health Care sector, specifically within Biotechnology. The company develops and manufactures rapid diagnostic kits for humans and animals, including immunochemical and fluorescence-based diagnostic products. It also produces raw materials such as antigens, antibodies, and enzymes, along with semi-finished products for diagnostic use. Listed on December 22, 2022, BioNote focuses on veterinary and human diagnostic solutions. BioNote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNote stock

On Eulerpool you can find the complete historical development of Debt-to-Equity Ratio BioNote since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Equity ratio measures financial leverage by comparing total debt to shareholders' equity. Higher ratios indicate more debt financing relative to equity.

Debt/Equity = Total Debt / Shareholders' Equity

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Equity Ratio's BioNote with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioNote

All Key Metrics — BioNote